While these are early days yet, these results collectively support the view that ultrastructural alterations within NaV1.5-rich nanodomains may be a key determinant of arrhythmia risk, and therefore, a potential target for antiarrhythmic therapy. The gene discussed is SCN5A; the disease is cardiac arrhythmia.